SANOFIBECAUSE HEALTH MATTERS

By Lakshmi Ananth

Jobin Thomas

HISTORY & LEGACY• Founded in 1956 4pas Hoechst Fedco Pharma pvt. Limited.• Merged with Roussel India Limited in 1997 to form Hoechst Marion Roussel

Limited.• Globally acquired Aventis in 2001 and rebranded as Sanofi (in May 2011)

Subsidiary Company Main OperationSanofi Pasteur (from 1996) Vaccine divisionShantha Biotechnics (from 1993)

Biotech company for research in rare diseases

Genzyme (from 2011) Recombinant health care productsChattem (from 2010) OTC productsZentiva Generic productsMedley Contract ManufacturingNichi-Iko & Merial Generic products

Major Therapeutic Areas

• Cardiovascular Diseases• Thrombosis• Diabetes• Internal Medicine• Veterinary Medicines

• Central Nervous System• Oncology• Arthritis and Osteoporosis• Consumer Health Care

Due to world-class R&D pipeline, Sanofi India has leading positions in the following major therapeutic areas:

SWOT AnalysisSTRENGTHS

• Fourth largest company by prescription sales• Market leadership in vaccines with Sanofi

Pasteur• Oncology pipeline has more than 15 molecules.• Usage of renewable energy for manufacturing

site• Very good in conducting Social Responsibilities

like tuberculosis awareness programmes, diabetes awareness programmes etc.,

OPPURTUNITIES• Can capture entire African Market and expansion

to new geographical areas.• Genzyme has given its considerable presence in

uncommon diseases.• Population growth and increase of purchasing

power of developing countries.• Marketing agreements with leading companies in

developing and developed countries.

SWOT AnalysisWEAKNESS

• Employee generated lot of negative publicity for company.

• Very small business units (Only 2 business units in Goa & Anklaleswar).

• Patent expiry of most of blockbuster drugs (Plavix® and Lovenox®).

• Low R&D productivity.

THREATS• Global economic slowdown as major of

company’s revenue is based on Exports.• Chance of losing market because of quality

Issues (Combiflam® withdrawal in May 2016).

• Stringent regulations in new drug development.

• Increase in generic competition.

LITERATURE & RESOURCES• Sanofi India Official Website(http://www.sanofi.in/)• Statement on the recall of Combiflam® batches, May 23rd 2016.• Financial Results for the Q1, June 30, 2016.• Zentiva International Website(http://www.zentiva.com/)• Shantha Biotechnics Website (http://shanthabiotech.com/)• Sanofi Genzyme Website (https://www.sanofigenzyme.com/)

Thank You.!BECAUSE HEALTH MATTERS

SANOFI